NCT03168061: Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma

NCT03168061
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 80 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for dose escalation phase (Part 1)
Exclusions: Patients with evidence of central nervous system metastasis & have not received prior definitive therapy for their lesions; Patients with prior exposure to >375 mg/m2 of doxorubicin or liposomal doxorubicin or ≥675 mg/m2 of nanoparticle epirubicin
https://ClinicalTrials.gov/show/NCT03168061

Comments are closed.

Up ↑